Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia

Wuhan Asia Heart Hospital

Status: Unknown

Conditions: Biomarkers; Thrombosis; Heparin-Induced Thrombocytopenia

Treatments: Diagnostic Test: HIT with thrombosis

Study type: Observational

Funder types: Other

Identifiers

NCT03269019

2017CX05

Details and patient eligibility

About

Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%. Early diagnosis of HIT and prevention of thrombosis is very important.

This study is planned to assess the use of thrombotic biomarkers in patients with HIT, including thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy monitoring . These biomarkers are monitored in 5-14 days post-operation to assess the risk of thrombosis in HIT patients. All patients were followed up for 30 days, and clinical outcomes, including new thrombus and death, were recorded during follow-up.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized patients undergoing cardiac surgery.
• Receiving unfractionated heparin anticoagulation.

Exclusion criteria

• history of heparin-induced thrombocytopenia
• pregnant woman

Trial design

200 participants in 3 patient groups

HIT-group

Description:

The patients with heparin-induced thrombocytopenia.

Treatment:

Diagnostic Test: HIT with thrombosis

HITTs-group

Description:

The patients with heparin-induced thrombocytopenia with thrombosis.

Treatment:

Diagnostic Test: HIT with thrombosis

Control group

Description:

The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.